Mar. 12 at 12:57 PM
$PPCB Propanc Biopharma, Inc. (PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced highlights of PRP, its lead proenzyme therapy poised to potentially disrupt the
$3 billion+ pancreatic cancer treatment market—one of oncology's most desperate battlegrounds with a grim 13% five-year survival rate.
Conventional chemo hits walls of resistance, brutal toxicity, and minimal progress. PRP changes the game:
- >85% tumor growth inhibition demonstrated in preclinical pancreatic models
- Forces malignant cells to differentiate—attacking cancer at its root
- Reduces fibrosis and resistance markers in the tumor microenvironment
- Sensitizes resistant tumors to standard chemo—higher efficacy, lower toxicity
- Targets cancer stem cells to cut recurrence risk
